علاج الفشل التنفسي المزمن في كوفيد-19 مع الفشل التنفسي الحاد أو متلازمة الضائقة التنفسية الحادة

References

DOI: 10.1186/s40560-023-00658-3

• A certain proportion of patients with COVID-19 develop ARF and ARDS depending on patient age, comorbidities, immune status, and SARS-CoV-2 virus genotype among other factors.
• These findings indicate that the management of ARF and ARDS in patients with COVID-19 should be the same as for other causes.
• However, parameters of mechanical ventilation, including PEEP, should be individualized based on the ventilatory and systemic condition of individual patients.
• Pharmacological therapies, including corticosteroids, should be administered according to the guidelines and statements specific to COVID-19.
• In addition to standard ventilatory management, the benefits of awake prone positioning for non-intubated patients have been posited and examined.